Advertisement
Canada markets open in 6 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7290
    -0.0008 (-0.11%)
     

  • CRUDE OIL

    82.29
    -0.52 (-0.63%)
     

  • Bitcoin CAD

    86,275.93
    -4,398.80 (-4.85%)
     

  • CMC Crypto 200

    1,345.33
    -37.25 (-2.69%)
     

  • GOLD FUTURES

    2,331.70
    -6.70 (-0.29%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.7210
    +0.0690 (+1.48%)
     

  • NASDAQ futures

    17,341.25
    -323.25 (-1.83%)
     

  • VOLATILITY

    16.86
    +0.89 (+5.57%)
     

  • FTSE

    8,056.90
    +16.52 (+0.21%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Stocks in play: Aeterna Zentaris Inc

Baystreet.ca

Through its wholly-owned subsidiary Aeterna Zentaris GmbH, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it is continuing to expand its development pipeline by initiating a preclinical development program to develop parathyroid hormone fusion polypeptides (PTH) with delayed clearance based on proprietary intellectual property exclusively licensed by Aeterna from The University of Sheffield, U.K. Aeterna Zentaris Inc. shares T.AEZS are trading up $0.08 at $1.35.

Read: Gold Prices May Be Done Falling, Says DoubleLine CEO